Better than Ambien? Minerva soars on PhIIb update on seltorexant for insomnia
A month after roiling investors with what skeptics dismissed as cherry picking of its depression data, Minerva is back with a clean slate of data from its Phase IIb insomnia trial.
In a detailed update, the Waltham, MA-based biotech said seltorexant (MIN-202) hit both the primary and several secondary endpoints, effectively improving sleep induction and prolonging sleep duration. Investigators made a point to note that the effects were consistent across the adult and elderly populations, with the latter more prone to the sleep disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.